• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Virchows Archiv >Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes
【24h】

Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes

机译：单克隆抗体HBME-1与少量绒毛状表面B细胞反应，可用于诊断毛状细胞白血病和绒毛B淋巴细胞的其他惰性淋巴细胞增生

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Hector Battifora mesothelial epitope-1 (HBME-1) monoclonal antibody has been generated against human mesothelioma cells and recognizes a biochemically unknown membrane epitope. We have accidentally found that the HBME-1 reacts with scattered lymphocytes showing villous surface in hyperplastic lymphoid tissue. To evaluate its reactivity pattern, we have performed a consecutive immunohistochemical study in nonneoplastic bone marrow and lymphoid samples (n = 40), as well as in malignant lymphoproliferations (n = 427), including hairy cell leukemia (HCL) (n = 72), HCL variant (HCL-v) (n = 13), splenic diffuse red pulp small B cell lymphoma (SDRPL) (n = 8), splenic B cell marginal zone lymphoma (SMZL) (n = 59), and splenic B cell lymphoma/leukemia, not further classifiable on bone marrow morphology (SBCL) (n = 37) cases. The staining pattern of HBME-1 was compared to DBA.44. HBME-1+ villous lymphocytes were constantly detected in low number in nonneoplastic lymphoid tissues. With multicolor immunofluorescence staining, HBME-1+ lymphocytes showed a CD20+/CD79a+/IgM+ B cell phenotype. In B cell lymphoproliferations of villous lymphocytes, HBME-1 reactivity was demonstrated in 96 % of HCL, 39 % of HCL-v, 50 % of SDRPL, 12 % of SMZL, and 19 % of SBCL cases. Nodal and extranodal marginal zone lymphoma cases were positive in 12 % of the cases. A small minority (4 %) of the other B cell lymphomas and no T cell lymphoma revealed tumor cell reactivity with HBME-1. In conclusion, our study has established that HBME-1 reacts with a minor subset of B lymphocytes and a small proportion of B cell lymphomas, which has not been described previously. We suggest that HBME-1 can be a useful marker in the diagnosis of HCL and other indolent lymphoproliferations of villous B lymphocytes.
机译：Hector Battifora间皮表位-1（HBME-1）单克隆抗体已针对人间皮瘤细胞产生，可​​识别生化未知的膜表位。我们意外地发现，HBME-1与增生性淋巴组织中呈绒毛状表面的分散淋巴细胞发生反应。为了评估其反应模式，我们已经在非肿瘤性骨髓和淋巴样样品（n = 40）和恶性淋巴增生（n = 427）中进行了连续的免疫组织化学研究，其中包括毛细胞白血病（HCL）（n = 72）。 ，HCL变体（HCL-v）（n =）13），脾弥漫性红髓小B细胞淋巴瘤（SDRPL）（n = 8），脾B细胞边缘区淋巴瘤（SMZL）（n = 59）和脾B细胞淋巴瘤/白血病，无法进一步分类为骨髓形态学（SBCL）（n = 37）。将HBME-1的染色模式与DBA.44进行了比较。在非肿瘤性淋巴组织中不断检测到少量的HBME-1 +绒毛状淋巴细胞。通过多色免疫荧光染色，HBME-1 +淋巴细胞显示出CD20 + / CD79a + / IgM + B细胞表型。在绒毛细胞的B细胞淋巴细胞增生中，在96％的HCL，39％的HCL-v，50％的SDRPL，12％的SMZL和19％的SBCL病例中证明了HBME-1反应性。结节和结外边缘区淋巴瘤病例中有12％呈阳性。少数（4％）其他B细胞淋巴瘤且无T细胞淋巴瘤显示肿瘤细胞与HBME-1有反应性。总之，我们的研究确定了HBME-1与少量的B淋巴细胞和小比例的B细胞淋巴瘤反应，这在以前没有描述。我们建议HBME-1可以作为诊断HCL和绒毛B淋巴细胞其他惰性淋巴细胞的有用标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号